Drug interactions
Ocrelizumab + Tisagenlecleucel
Severity: Major
Ocrelizumab and Tisagenlecleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tisagenlecleucel is a CD19-directed CAR-T therapy that causes B-cell aplasia, and ocrelizumab also depletes B cells. Together they add to immunosuppression and the risk of serious infection. The two agents also act against the same cell population, so their therapeutic purposes overlap.
What this interaction means in plain words
Ocrelizumab and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Ocrelizumab belongs to Central Nervous System; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive B-cell depletion and immunosuppression from the two agents.
What to do
Avoid combining them; ocrelizumab should not be continued around CAR-T therapy unless specialist review supports it. Monitor closely for infection and check immunoglobulin levels if they are used together.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ocrelizumab and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ocrelizumab
- Adenovirus types 4 and 7 live + Ocrelizumab Contraindicated
- Influenza virus vaccine quadrivalent intranasal + Ocrelizumab Contraindicated
- Measles mumps and rubella vaccine live + Ocrelizumab Contraindicated
- Measles mumps rubella and varicella vaccine live + Ocrelizumab Contraindicated
- Measles vaccine + Ocrelizumab Contraindicated
- Anti-thymocyte + Ocrelizumab Major
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Ocrelizumab with Tisagenlecleucel?
MediHelp rates the interaction as major. Ocrelizumab and Tisagenlecleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Tisagenlecleucel is a CD19-directed CAR-T therapy that causes B-cell aplasia, and ocrelizumab also depletes B cells. Together they add to immunosuppression and the risk of serious infection. The two agents also act against the same cell population, so their therapeutic purposes overlap.
How serious is the interaction between Ocrelizumab and Tisagenlecleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining them; ocrelizumab should not be continued around CAR-T therapy unless specialist review supports it. Monitor closely for infection and check immunoglobulin levels if they are used together.
What other medicines interact with Ocrelizumab?
MediHelp also lists interactions of Ocrelizumab with, for example, Adenovirus types 4 and 7 live, Influenza virus vaccine quadrivalent intranasal, Measles mumps and rubella vaccine live. The full list is on the Ocrelizumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
